Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | PTGFR | P43088 | 2/20 | 0.48 |
| ▸ | PTGIR | P43119 | 2/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124438 | 1.00 | PTGS2 (0.55) | PTGS2CA1CA2NFKB1CA4 | |
| SCHEMBL5009953 | 0.87 | PTGS2 (0.48) | PTGS2CA1CA2NFKB1CA4 | |
| SCHEMBL7004841 | 0.85 | PTGS2 (0.55) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL7004850 | 0.85 | PTGS2 (0.55) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL211297 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL29393232 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL12852987 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL322878 | 0.84 | HDAC1 (0.65) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL9652685 | 0.83 | PTGS2 (0.54) | PTGS2NFKB1MAPTLMNANPC1 | |
| SCHEMBL11462614 | 0.82 | HDAC1 (0.62) | CA1CA2NFKB1CA4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930859-A | Cinnamic acid modified polyarylene sulfide and preparation method thereof | 新凝合科技(成都)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4367105-A1 | N-(1,3,4-OXADIAZOL-2-YL)PHENYLCARBOXAMIDES AS HERBICIDES | Bayer Aktiengesellschaft (DE) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023280772-A1 | N-(1,3,4-OXADIAZOL-2-YL)PHENYLCARBOXAMIDES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-12 | — | — | WO | disclosed |
| EP-3713417-A1 | HERBICIDALLY ACTIVE BICYCLIC BENZAMIDES | Bayer Aktiengesellschaft (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3638665-A1 | HERBICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES OF TETRAHYDRO AND DIHYDROFURAN CARBOXYLIC ACIDS AND ESTERS | Bayer Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014090765-A1 | USE OF 1-[2-FLUORO-4-METHYL-5-(2,2,2-TRIFLUOROETHYLSULFINYL)PHENYL]-5-AMINO-3-TRIFLUOROMETHYL)-1 H-1,2,4 TFIA ZOLE FOR CONTROLLING NEMATODES IN NEMATODE-RESISTANT CROPS | BAYER CROPSCIENCE AG (DE) | 2014-06-19 | — | — | WO | disclosed |
| EP-2531506-B1 | Spiroindoline compounds for use as anthelminthics | INTERVET INT BV (NL) | 2014-05-14 | — | — | EP | disclosed |
| US-6506940-B1 | Converting sertraline stereoisomer into imine form of sertraline; reducing into cis (1S,4S) sertraline and byproduct stereoisomer of sertraline; recovering cis (1S,4S) sertraline from reaction mixture; repeating | SUN PHARMACEUTICALS INDUSTRIES LTD. (IN) | 2003-01-14 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001049638-A2 | A PROCESS FOR CONVERTING STEREOISOMERS OF SERTRALINE INTO SERTRALINE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2001-07-12 | — | — | WO | disclosed |
| US-5863936-A | HETEROCYCLIC ENZYME INHIBITORS AS ANTICANCER AGENTS | GERON CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5677306-A | ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS | RHONE-POULENC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
| US-5113477-A | Core, cladding, heat resistance | HITACHI, LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0213892-B1 | HERBICIDALLY ACTIVE ENOLS | ROHM AND HAAS COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| US-5017723-A | Psychotropic Agents | JOUVEINAL S.A. (FR) | 1991-05-21 | — | — | US | disclosed |
| EP-0351856-A2 | Thiazolo[5,4-b]azepine compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0226020-A2 | Plastic optical fibers and transparent resin used therefor | HITACHI, LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | PTGS2 156/4885CA1 3866/4885CA2 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.